MarshallRPosnerMD

Head & Neck Cancer

Professor of Medicine, Icahn School of Medicine at Mount Sinai; Medical Director, Head and Neck Oncology; co-Director Cancer Clinical Investigation Program, Tisch Cancer Institute

Request Appointment

Overview of Dr. Posner

Dr. Marshall Posner is an oncologist in New York, NY and is a professor of medicine at Mount Sinai Hospital. He received his BA from Yale University and his medical degree from Tufts University School of Medicine and has been in practice 40+ years. He specializes in clinical trials, immunotherapy, and head and neck oncology. He is Medical Director of the Head and Neck Oncology Program at Mount Sinai and co-director of the Cancer Clinical Investigation Program for the Tisch Caner Institute. He has over 275 peer reviewed publications and numerous patents.

Office
1630 S Congress Ave
West Palm Beach, FL 33410
Book by Phone+1(878) 309-1140

Fax+1 561-253-3985

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1978 - 1981
Boston University Medical CenterResidency, Internal Medicine, 1975 - 1978
Tufts University School of MedicineClass of 1975

Certifications & Licensure

FL State Medical License 2020 - 2026
NY State Medical License 2010 - 2026
MA State Medical License 1978 - 2019
RI State Medical License 1983 - 1992
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2011-2014
America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
New York Magazine: Top Doctors Castle Connolly, 2011, 2013
Boston Magazine Castle Connolly, 2008-2009
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Chemotherapy Plus Radiation Therapy in Treating Patients With Squamous Cell Cancer of the Head and Neck Start of enrollment: 1995 Oct 01
Completed
Phase 1
Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Start of enrollment: 1998 Nov 01
Completed
Phase 2
Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer Start of enrollment: 1999 Oct 01
Completed
Phase 2
ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer Start of enrollment: 1999 Jul 01
Withdrawn
Phase 1
Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 1997 Jan 01
Completed
Phase 2
Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 1997 Oct 01
Completed
Phase 1, Phase 2
Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 1998 Feb 01
Completed
Phase 1, Phase 2
Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer Start of enrollment: 1999 May 01
Completed
Phase 3
A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma Start of enrollment: 2009 Apr 01
Completed
Phase 2
Cabazitaxel - PF Induction Chemotherapy Start of enrollment: 2011 Apr 01
Completed
Phase 1
The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer Start of enrollment: 2012 Sep 01
Active, not recruiting
Phase 3
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy Start of enrollment: 2013 Oct 01
Terminated
Phase 2
ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer Start of enrollment: 2013 Dec 01
Completed
Phase 2
The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL) Start of enrollment: 2014 Mar 01
Completed
Not Applicable
Quarterback 2b - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer Start of enrollment: 2016 Apr 25
Active, not recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

The Common Expression of INSM1 in HPV-related Oropharyngeal Squamous Cell Carcinomas Is Not Associated With True Neuroendocrine Transformation or Aggressive Behavior.
Swati Bhardwaj, Brandon Veremis, Rocco Fernandino, Marshall Posner, William H Westra
The American Journal of Surgical Pathology. 2025-01-01
Association of human papillomavirus genotype and phylogenic clade with oropharyngeal cancer outcomes.
Michael T Wotman, Tara Ivic-Pavlicic, William H Westra, Brandon Gold, Megan D'Andrea
The Oncologist. 2024-11-04
1 citations
Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer.
Glenn J Hanna, Jamie Jabalee, John N Lukens, Lova Sun, Eleni M Rettig
Oral Oncology. 2024-11-01

Press Mentions

Optimizing Multidisciplinary Care for Patients with Head and Neck Cancer in a Community SettingDecember 1st, 2024
Drug Combo Shows Promise Against Advanced Head and Neck CancerApril 4th, 2023
Woman, 36, Recalls Being Diagnosed with Cervical Cancer While Pregnant with 1st ChildFebruary 1st, 2023
Join now to see all

Grant Support

Ebv-Specific T-Cell Therapy For Nasopharynx Cancer: Immunomodulation And ResponseNational Cancer Institute2008–2009
Functional Mechanisms Of Antibody Inhibition Of HIV-1National Institute Of Allergy And Infectious Diseases2005–2008
Functional Mechanisms Of Antibody Inhibition Of HIV-1National Institute Of Allergy And Infectious Diseases2005
Human Monoclonal Antibodies To Study And Treat HIVNational Institute Of Allergy And Infectious Diseases2000–2003
Human Monoclonal Antibodies To Study And Treat HIV 1National Institute Of Allergy And Infectious Diseases1996–1998
Human Monoclonal Antibodies To Study And Treat HIV-1National Institute Of Allergy And Infectious Diseases1994–1995
Human Monoclonal Antibodies To Study And Treat HIV-1National Institute Of Allergy And Infectious Diseases1993
Human Monoclonal Antibodies To Study And Treat LeukemiasNational Cancer Institute1991–1992
HIV-1 Infection Using Human Monoclonal AntibodiesNational Institute Of Allergy And Infectious Diseases1990
Human Monoclonal Antibodies To Study And Treat LeukemiasNational Cancer Institute1990
HIV-1 Infection Using Human Monoclonal AntibodiesNational Institute Of Allergy And Infectious Diseases1988–1990
Human Myeloma Analogues For Making Monoclonal AntibodiesNational Cancer Institute1985–1987

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Choice
First Health PPO
GHI PPO
Great West PPO
Health Net Oregon PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
ODS Network
Oxford Health Freedom
Oxford Health Liberty
Premera BCBS Heritage & Heritage Plus 1
Providence Health System Personal Option
Regence Washington - Preferred Provider Network
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment